Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: A single-blind, intrapatient left-to-right controlled study†
Article first published online: 19 FEB 2013
Copyright © 2013 Wiley Periodicals, Inc.
Lasers in Surgery and Medicine
Special Issue: Dermatology and Plastic Surgery
Volume 45, Issue 2, pages 102–107, February 2013
How to Cite
Huang, Y.-C., Chou, C.-L. and Chiang, Y.-Y. (2013), Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: A single-blind, intrapatient left-to-right controlled study. Lasers Surg. Med., 45: 102–107. doi: 10.1002/lsm.22122
- Issue published online: 25 FEB 2013
- Article first published online: 19 FEB 2013
- Manuscript Accepted: 26 DEC 2012
- pulsed dye laser;
- psoriatic nail;
Nail psoriasis is difficult to treat. The efficacy of pulsed dye laser (PDL) therapy for nail psoriasis has been reported in non-placebo controlled studies.
To evaluate the efficacy and safety of PDL with topical retinoid in the treatment of nail psoriasis.
The study was an intrapatient, left-to-right controlled trial of PDL in 25 patients with recalcitrant, bilateral fingernail psoriasis recruited between February 2011 and August 2011. We included two groups of patients: (1) patients with severe psoriasis who were receiving stable systemic therapy (phototherapy and systemic medication); (2) patients with mild psoriasis who were not receiving systemic therapy. One hand received the experimental treatment (PDL and tazarotene 0.1% cream) and the other, the control treatment (tazarotene 0.1% cream). All five fingernails of the experimental hand were treated with 595-nm PDL once a month for 6 months. Assessments included the modified Nail Psoriasis Severity Index (NAPSI) at baseline, 3, and 6 months, the Physician's Global Assessment at 3 and 6 months, the patient's global assessment, and adverse events.
Nineteen patients completed the 6-month protocol. The mean decrease in modified NAPSI score from baseline to 6 months was significantly more after the experimental treatment than the control treatment. Physician's global assessment showed significantly higher percentage of patients had ≥75% improvement at 6 months in the experimental group than the control group (31.6% vs. 5.3%, P = 0.045). Scores on the patient's global assessment were significantly higher in the experimental group than the control group (P < 0.001).
PDL plus topical tazarotene 0.1% cream is an effective and safe therapy in the treatment of nail psoriasis. Lasers Surg. Med. 45: 102–107, 2013. © 2013 Wiley Periodicals, Inc.